A major reorganization of the U.S. Department of Health and Human Services (HHS) — including massive cuts to the federal workforce — threatens scientific progress that drives our economy and improves the public’s health. Slashing federal funding and staff will hobble the very agencies that fuel medical discoveries and approve new treatments. In addition, the...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * CABOMETYX® Receives FDA Approval to Treat Neuroendocrine Tumors On March 26, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with...
Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai, has been elected Fellow of the American Association for the Advancement of Science (AAAS) — one of the world’s largest and most prestigious scientific societies and publisher of the Science journals. The lifetime honor recognizes...
Three decades of landmark research into type 2 diabetes prevention abruptly ended this month due to government funding cuts. The Endocrine Society calls on the administration to restore the Diabetes Prevention Program (DPP) and DPP Outcomes Study funded through the National Institutes of Health. The Society is concerned about how the loss of this ongoing...
On March 18, Queen’s University in Kington, Ontario, Canada, announced that Lisa Tannock, MD, was appointed dean, Queen’s Health Sciences, and director of the School Medicine, effective July 1. Tannock will join Queen’s University from the University of Kentucky, where she is associate provost for faculty advancement and a professor in the Division of Endocrinology,...
A third generation of the latest cholesterol-lowering medication — PCSK9-inhibitors — will soon be available for patients with homozygous familial hypercholesterolemia (HoFH), according to a January 24 article in The Lancet Diabetes & Endocrinology. Affecting approximately 30,000 individuals worldwide, HoFH is a rare but serious genetic disorder in which patients have markedly elevated levels (>10...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized weight loss management, and researchers are now exploring how these medications can further transform obesity care and offer new possibilities for long-term weight management, according to a recent review article published in Endocrinology. Authors Lauren A. Jones and Daniel I. Brierley, PhD, both of the Centre for Cardiovascular...
On March 13, the Board of Trustees of the University of Pennsylvania voted unanimously to appoint Endocrine Society Past-President J. Larry Jameson, MD, PhD, who has served as interim president since December 2023, president of the University for a term that will run through June 30, 2027. In announcing the appointment, Chair of the Board...
Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai, has been elected Fellow of the American Association for the Advancement of Science (AAAS) — one of the world’s largest and most prestigious scientific societies and publisher of the Science journals. The lifetime honor recognizes...
On March 13, the Board of Trustees of the University of Pennsylvania voted unanimously to appoint Endocrine Society Past-President J. Larry Jameson, MD, PhD, who has served as interim president since December 2023, president of the University for a term that will run through June 30, 2027. In announcing the appointment, Chair of the Board...
